Neoadjuvant Radiotherapy for HCC Involving Type I PVTT

Neoadjuvant Radiotherapy for Patients With Hepatocellular Carcinoma Involving Type I Portal Vein Tumor Thrombus

The rate of patients with hepatocellular carcinoma (HCC) involving portal vein tumor thrombus (PVTT) is up to 50% in Guangxi province, China. Some of them will receive hepatic resection, especially those with type I or II PVTT. However, 5-years recurrence rate is up to 75% after surgery. Some retrospective studies found postoperative radiotherapy may reduce the rate of recurrence. Moreover, few retrospective studies also found neoadjuvant radiotherapy (PMID: 27317960) may improve overall survival for HCC patients involving type II/III PVTT. However, the safety and efficacy of neoadjuvant raidotherapy for HCC involving type I PVTT is unknown.

Inclusion Criteria:

• Age 18-75 years;
• Patients with resectable primary hepatocellular carcinoma and Cheng's type I portal vein tumor thrombus;
• Child-Pugh A or B (7 score) liver function;
• With more than 3 months expected survival;
• The volume of residual liver more than 30%;
• Patients agree to take part in.

Exclusion Criteria:

• Patients with primary hepatocellular carcinoma and Cheng's type II/III/IV portal vein tumor thrombus
• Previous history of epigastric radiotherapy
• With extrahepatic metastasis
• With radiotherapy contraindication;
• Pregnant woman or sucking period;
• With repture tumor;
• With other cancer in previous five years;
• With chemothrapy, target therapy or immunosuppressive drugs therapy.